{
    "nct_id": "NCT05380635",
    "official_title": "Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment",
    "inclusion_criteria": "* A clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosis fungoides), Stage IB or Stage IIA\n* CTCL lesions covering â‰¥ 10% of their body surface area\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of allergy or hypersensitivity to any of the components of HyBryte\n* Pregnancy or mothers who are breast-feeding\n* Males and females not willing to use effective contraception\n* Subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g., porphyria, systemic lupus erythematosus (SLE), Sjogren's syndrome, etc.)\n* Subjects whose condition is spontaneously improving\n* Subjects receiving topical steroids or other topical treatments (e.g., nitrogen mustard) on index lesions for CTCL within 2 weeks of enrollment\n* Subjects receiving systemic steroids, psoralen ultraviolet A (UVA) radiation therapy (PUVA), narrow band ultraviolet B (UVB) light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment\n* Subjects who have received electron beam irradiation within 3 months of enrollment\n* Subjects with a history of significant systemic immunosuppression\n* Subjects taking other investigational drugs or drugs of abuse within 30 days of enrollment\n* Subjects receiving drugs known to cause photosensitization within 2 weeks of starting HyBryte therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks",
    "miscellaneous_criteria": ""
}